Patents by Inventor Frank Osterkamp

Frank Osterkamp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10799605
    Abstract: The present invention is related to a conjugate comprising a structure of general formula (1) [TM1]-[AD1]-[LM]-[AD2]-[TM2] (1), wherein TM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target, AD1 is a first adapter moiety or is absent, LM is a linker moiety or is absent, AD2 is a second adapter moiety or is absent, and TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target; wherein the first targeting moiety and/or the second targeting moiety is a compound of formula (2): wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2 adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: October 13, 2020
    Assignee: 3B Pharmaceuticals GMBH
    Inventors: Frank Osterkamp, Christian Haase, Ulrich Reineke, Christiane Smerling, Matthias Paschke, Jan Ungewiß
  • Patent number: 10800816
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: October 13, 2020
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Michael Dockal, Rudolf Hartmann, Friedrich Scheiflinger, Frank Osterkamp, Thomas Polakowski, Ulrich Reineke
  • Publication number: 20190134147
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.
    Type: Application
    Filed: January 14, 2019
    Publication date: May 9, 2019
    Applicants: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
  • Patent number: 10201586
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: February 12, 2019
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
  • Patent number: 10196423
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: February 5, 2019
    Assignee: Shire Orphan Therapies GmbH
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Helberg
  • Publication number: 20180334477
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Application
    Filed: May 9, 2018
    Publication date: November 22, 2018
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Helberg
  • Patent number: 10124033
    Abstract: The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: November 13, 2018
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Michael Dockal, Thomas Polakowski, Frank Osterkamp, Rudolf Hartmann, Matthias Paschke, Bettina Hartlieb, Friedrich Scheiflinger
  • Publication number: 20180155399
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
    Type: Application
    Filed: November 16, 2017
    Publication date: June 7, 2018
    Applicants: Baxalta GmbH, Baxalta Incorporated
    Inventors: Michael DOCKAL, Rudolf HARTMANN, Friedrich SCHEIFLINGER, Frank OSTERKAMP, Thomas POLAKOWSKI, Ulrich REINEKE
  • Patent number: 9982016
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: May 29, 2018
    Assignee: Shire Orphan Therapies GmbH
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
  • Patent number: 9873720
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: January 23, 2018
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Michael Dockal, Rudolf Hartmann, Friedrich Scheiflinger, Frank Osterkamp, Thomas Polakowski, Ulrich Reineke
  • Publication number: 20170313743
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Application
    Filed: July 10, 2017
    Publication date: November 2, 2017
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
  • Patent number: 9745344
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: August 29, 2017
    Assignee: Shire Orphan Therapies GmbH
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
  • Publication number: 20170174727
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
    Type: Application
    Filed: December 29, 2014
    Publication date: June 22, 2017
    Applicants: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: MICHAEL DOCKAL, RUDOLF HARTMANN, FRIEDRICH SCHEIFLINGER, FRANK OSTERKAMP, THOMAS POLAKOWSKI, ULRICH REINEKE
  • Publication number: 20170157198
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.
    Type: Application
    Filed: December 9, 2016
    Publication date: June 8, 2017
    Applicants: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
  • Publication number: 20170119913
    Abstract: The present invention is related to a conjugate comprising a structure of general formula (1) [TM1]-[AD1]-[LM]-[AD2]-[TM2] (1), wherein TM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target, AD1 is a first adapter moiety or is absent, LM is a linker moiety or is absent, AD2 is a second adapter moiety or is absent, and TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target; wherein the first targeting moiety and/or the second targeting moiety is a compound of formula (2): wherein R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2 adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.
    Type: Application
    Filed: June 10, 2015
    Publication date: May 4, 2017
    Inventors: Frank Osterkamp, Christian Haase, Ulrich Reineke, Christiane Smerling, Matthias Paschke, Jan Ungewiß
  • Publication number: 20170035835
    Abstract: The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.
    Type: Application
    Filed: August 19, 2016
    Publication date: February 9, 2017
    Inventors: Michael Dockal, Thomas Polakowski, Frank Osterkamp, Rudolf Hartmann, Matthias Paschke, Bettina Hartlieb, Friedrich Scheiflinger
  • Patent number: 9556230
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: January 31, 2017
    Assignees: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
  • Patent number: 9458198
    Abstract: Disclosed are cyclic, peptide-based novel compounds having NPR-B agonistic activity. Preferred compounds are cyclic peptides containing conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds. In some embodiments, provided herein are a cyclic peptide compound with a ring size that is significantly reduced as compared to known NPR-B agonists, such as CNP.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: October 4, 2016
    Assignee: Shire Orphan Therapies GmbH
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg
  • Patent number: 9447147
    Abstract: The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: September 20, 2016
    Assignees: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: Michael Dockal, Thomas Polakowski, Frank Osterkamp, Rudolf Hartmann, Matthias Paschke, Bettina Hartlieb, Friedrich Scheiflinger
  • Patent number: 9169293
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: October 27, 2015
    Assignee: Shire Orphan Thereapies GmbH
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Bernadett Simon, Uwe Richter, Edgar Specker, Markus Woischnik, Mark R. Hellberg